接受溴隐亭治疗的血泌乳素正常的不育男性的垂体功能

Pituitary function in normoprolactinaemic infertile men receiving bromocriptine.

作者信息

Glatthaar C, Donald R A, Smith R, McRae C U

出版信息

Clin Endocrinol (Oxf). 1980 Nov;13(5):455-9. doi: 10.1111/j.1365-2265.1980.tb03411.x.

DOI:10.1111/j.1365-2265.1980.tb03411.x

Abstract

A double blind trial of bromocriptine 7.5 mg daily versus placebo was carried out in ten infertile men. Pretreatment basal plasma prolactin, thyroid stimulating hormone (TSH) testosterone and luteinizing hormone (LH) concentrations were normal, but plasma follicle-stimulating-hormone (FSH) was raised in four individuals. After 4 months treatment with bromocriptine a significant fall in plasma prolactin was observed (P less than 0.01), both under basal conditions and following thyroid stimulating hormone releasing hormone (TRH). Basal plasma gonadotrophin, testosterone and thyroid stimulating hormone (TSH) concentrations did not alter. No change in sperm density, volume or motility was noted. However an apparent fall in the peak plasma LH (but not FSH) response to gonadotrophin releasing hormone (LHRH) was observed in patients receiving bromocriptine. This reduction in plasma LH responsiveness was significant when compared with the baseline response (P less than 0.05) but failed to reach significance when compared with the placebo response. It is concluded that prolonged bromocriptine therapy in normoprolactinaemic men does not suppress FSH secretion, and any reduction in plasma LH responsiveness to LHRH is not accompanied by a significant fall in plasma testosterone.

摘要

对10名不育男性进行了一项双盲试验，比较每日服用7.5毫克溴隐亭与服用安慰剂的效果。治疗前基础血浆催乳素、促甲状腺激素（TSH）、睾酮和促黄体生成素（LH）浓度均正常，但4名个体的血浆促卵泡生成素（FSH）升高。用溴隐亭治疗4个月后，观察到基础状态下以及注射促甲状腺激素释放激素（TRH）后血浆催乳素均显著下降（P<0.01）。基础血浆促性腺激素、睾酮和促甲状腺激素（TSH）浓度未改变。精子密度、体积或活力未见变化。然而，在接受溴隐亭治疗的患者中，观察到血浆LH（而非FSH）对促性腺激素释放激素（LHRH）的峰值反应明显下降。与基线反应相比，血浆LH反应性的这种降低具有显著性（P<0.05），但与安慰剂反应相比未达到显著性。结论是，正常催乳素血症男性长期使用溴隐亭治疗不会抑制FSH分泌，血浆LH对LHRH反应性的任何降低均未伴有血浆睾酮的显著下降。